JadiCell COVID-19 is under clinical development by Therapeutic Solutions International and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury. According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the JadiCell COVID-19 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JadiCell COVID-19 overview
The therapeutic candidate is under development for the treatment of Coronavirus Disease 2019 (COVID-19) associated acute respiratory distress syndrome and acute lung injury. It is administered through intravenous route. The therapeutic candidate consists of universal donor adult mesenchymal stem cells generated from umbilical cords.
Therapeutic Solutions International overview
Therapeutic Solutions International (Therapeutic Solutions) is a pharmaceutical company that developed immune modulation for the treatment of several specific diseases. The company product pipeline includes ARDScells, JadiCell ARDS, CTEcells, StemVacs-A, StemVacs-V, ALScells, StemVacs-E, StemVacs-P, StemVacs-L, JadiCell_DC_Exosomes, JadiCell Lithium, JadiCell Schizophrenia, LymphoBoost, JadiCell Neurogenesis, NarcoStem. The therapeutic Solutions pipeline also includes NeuroLeukin, CampbellCell, siRNA ARDS, RNA/CTE and VSX-001. Therapeutic Solutions is headquartered in Oceanside, California?, the US.
For a complete picture of JadiCell COVID-19’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.